Cargando…
Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients
We have analysed DNA extracted from the serum and peritoneal fluid of 20 ovarian cancer patients for the presence of tumour-specific genetic alterations. The 20 patients included six with stage Ia disease. Using six polymorphic microsatellite loci we were able to detect novel alleles or loss of hete...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363116/ https://www.ncbi.nlm.nih.gov/pubmed/10468300 http://dx.doi.org/10.1038/sj.bjc.6690601 |
_version_ | 1782153624236851200 |
---|---|
author | Hickey, K P Boyle, K P Jepps, H M Andrew, A C Buxton, E J Burns, P A |
author_facet | Hickey, K P Boyle, K P Jepps, H M Andrew, A C Buxton, E J Burns, P A |
author_sort | Hickey, K P |
collection | PubMed |
description | We have analysed DNA extracted from the serum and peritoneal fluid of 20 ovarian cancer patients for the presence of tumour-specific genetic alterations. The 20 patients included six with stage Ia disease. Using six polymorphic microsatellite loci we were able to detect novel alleles or loss of heterozygosity in 17/20 serum samples and 12/19 peritoneal fluid samples. Tumour-specific abnormalities were detected in the serum of all but one of the stage Ia cases. Half of the occurrences of loss of heterozygosity identified in primary tumour material were detectable in the serum samples. Novel alleles indicative of microsatellite instability were found in 3/6 patients with stage Ia disease but in only 1/14 of patients with more advanced disease. One of the eight patients in the control group displayed abnormalities in her serum DNA. The ease with which tumour-specific alterations were detected in serum and peritoneal samples from ovarian cancer patients, using a panel of only six polymorphic microsatellite markers on four chromosomes, suggests that molecular detection methods could prove useful in the staging, monitoring and screening of this disease. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2363116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23631162009-09-10 Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients Hickey, K P Boyle, K P Jepps, H M Andrew, A C Buxton, E J Burns, P A Br J Cancer Regular Article We have analysed DNA extracted from the serum and peritoneal fluid of 20 ovarian cancer patients for the presence of tumour-specific genetic alterations. The 20 patients included six with stage Ia disease. Using six polymorphic microsatellite loci we were able to detect novel alleles or loss of heterozygosity in 17/20 serum samples and 12/19 peritoneal fluid samples. Tumour-specific abnormalities were detected in the serum of all but one of the stage Ia cases. Half of the occurrences of loss of heterozygosity identified in primary tumour material were detectable in the serum samples. Novel alleles indicative of microsatellite instability were found in 3/6 patients with stage Ia disease but in only 1/14 of patients with more advanced disease. One of the eight patients in the control group displayed abnormalities in her serum DNA. The ease with which tumour-specific alterations were detected in serum and peritoneal samples from ovarian cancer patients, using a panel of only six polymorphic microsatellite markers on four chromosomes, suggests that molecular detection methods could prove useful in the staging, monitoring and screening of this disease. © 1999 Cancer Research Campaign Nature Publishing Group 1999-08 /pmc/articles/PMC2363116/ /pubmed/10468300 http://dx.doi.org/10.1038/sj.bjc.6690601 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Hickey, K P Boyle, K P Jepps, H M Andrew, A C Buxton, E J Burns, P A Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients |
title | Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients |
title_full | Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients |
title_fullStr | Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients |
title_full_unstemmed | Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients |
title_short | Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients |
title_sort | molecular detection of tumour dna in serum and peritoneal fluid from ovarian cancer patients |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363116/ https://www.ncbi.nlm.nih.gov/pubmed/10468300 http://dx.doi.org/10.1038/sj.bjc.6690601 |
work_keys_str_mv | AT hickeykp moleculardetectionoftumourdnainserumandperitonealfluidfromovariancancerpatients AT boylekp moleculardetectionoftumourdnainserumandperitonealfluidfromovariancancerpatients AT jeppshm moleculardetectionoftumourdnainserumandperitonealfluidfromovariancancerpatients AT andrewac moleculardetectionoftumourdnainserumandperitonealfluidfromovariancancerpatients AT buxtonej moleculardetectionoftumourdnainserumandperitonealfluidfromovariancancerpatients AT burnspa moleculardetectionoftumourdnainserumandperitonealfluidfromovariancancerpatients |